Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 19Lymphoma 5Lung Neoplasms 5Multiple Myeloma 4Lymphoma, Large-Cell, Anaplastic 4Neuroblastoma 3Neoplasms 2Hematologic Neoplasms 2Carcinoma 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Neurofibromatosis 2 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Lobular 1Carcinoma, Large Cell 1Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer 1Advanced Cancer 1Adenocarcinoma of Lung 1Adenocarcinoma 1ALK-positive NSCLC 1ALK or ROS1-positive NSCLC 1

Interventions

Nivolumab 11Ipilimumab 6linrodostat 4relatlimab 3Pemetrexed 2tislelizumab 1regorafenib 1ralimetinib 1p38 Mitogen-Activated Protein Kinases 1mirdametinib 1gedatolisib 1figitumumab 1efatutazone 1abemaciclib 1Vorinostat 1Tetanus Toxoid 1Tamoxifen 1Sunitinib 1Ranitidine 1Midazolam 1LY2603618 1LY2584702 1Irinotecan 1Gemcitabine 1Fulvestrant 1Dasatinib 1Cyclophosphamide 1Crizotinib 1Cetuximab 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Cancer × Crizotinib × Clear all
NCT01576406 2018-10-25

Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients

Pfizer

Phase 1 Completed
88 enrolled 44 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡